CellCept

Aurinia lupus candidate hits PhII target, but deaths send stock down

Aurinia Pharmaceuticals has posted positive new data for its experimental drug voclosporin for active lupus nephritis--but 12 deaths in the study's treatment arm has sent alarm bells ringing.

Ben Adams Aug 15, 2016 8:27am